<DOC>
	<DOCNO>NCT00705939</DOCNO>
	<brief_summary>Gaucher disease , prevalent lysosomal storage disorder , cause mutation human glucocerebrosidase gene ( GCD ) lead reduce activity lysosomal enzyme glucocerebrosidase thereby accumulation substrate glucocerebroside ( GlcCer ) cell monocyte-macrophage system . This extension trial Study NCT00376168 NCT00712348 .</brief_summary>
	<brief_title>Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial</brief_title>
	<detailed_description>This multi-center , double-blind , parallel group , extension trial ass safety efficacy prGCD patient complete NCT00376168 . Patients receive IV infusion prGCD every two week select medical center . The duration extension study fifteen month . There two treatment group : 30 units/kg every 2 week 60 units/kg every 2 week .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Successful completion Protocol PB06001 The patient sign inform consent Currently take another experimental drug condition Presence severe neurological sign symptom , define complete ocular paralysis , overt myoclonus history seizure , characteristic neuronopathic Gaucher disease Pregnant nursing Presence medical , emotional , behavioral psychological condition judgment Investigator would interfere patient 's compliance requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Gaucher Disease</keyword>
	<keyword>Enzyme replacement therapy</keyword>
</DOC>